Systematic review identifies specific medications significantly associated with drug-induced hyperpigmentation across diverse drug classes.
These Common Meds Might Be Darkening Your Skin
A systematic review and meta-analysis evaluated twenty-two studies regarding the incidence of drug-induced hyperpigmentation. The analysis f…
A major review reveals many common medicines can cause noticeable skin darkening.
Concurrent anti-VEGF and anticoagulant use in cancer patients with VTE shows rare bleeding events
Can You Take Blood Thinners With Cancer Drugs Safely?
This retrospective analysis at Hunan Cancer Hospital assessed 208 patients receiving concurrent anti-VEGF agents and anticoagulants for VTE.…
New research suggests it is generally safe to use blood thinners with certain cancer treatments.
Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma.
Triple therapy offers a 52% chance of living three years with advanced liver cancer.
This retrospective cohort study evaluated 270 patients with unresectable hepatocellular carcinoma receiving first-line triple therapy across…
Patients with advanced liver cancer receiving triple therapy had a 52% chance of surviving three years, offering new hope for those facing d…
Meta-analysis of TKI combinations in glioblastoma shows improved PFS and ORR with mixed safety signals.
New Hope for Glioblastoma Patients Emerges
This meta-analysis evaluated combination treatments incorporating tyrosine kinase inhibitors (TKIs) versus TKI-free control regimens in 1,43…
Imagine getting the hardest diagnosis a person can hear: a fast-growing brain tumor with few good treatment options.
Radical nephrectomy performed for renal inflammatory myofibroblastic tumor in an elderly female.
Rare Kidney Tumor Treated Successfully With Surgery Alone
This is a case report of an elderly female patient who underwent radical right nephrectomy for a renal inflammatory myofibroblastic tumor. T…
A rare kidney tumor was removed with surgery, and no recurrence was seen at 6 months. But this is just one case.
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma.
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
Can a simple test find the right drug to save children with tough leukemia?
A prospective, multicenter Drug Response Profiling registry of 340 children with relapsed or refractory acute lymphoblastic leukemia in 17 E…
A simple test matching leukemia drugs to patient cells helped 68% of children respond to treatment and gave 28 of 42 patients a chance to su…
Immune checkpoint inhibitor regimens improve survival versus tyrosine kinase inhibitor monotherapies in advanced hepatocellular carcinoma
The Liver Cancer Treatment That Works Better Depending on Your History
This systematic review and meta-analysis of seventeen studies evaluated immune checkpoint inhibitor (ICI)-based regimens versus tyrosine kin…
Immunotherapy beats older drugs for advanced liver cancer, especially when hepatitis B caused the disease, but benefits depend on your liver…
In L858R-mutated NSCLC, ICI combinations improve progression-free survival versus chemotherapy in TKI-resistant patients.
Immune Drugs Work in This Lung Cancer, But Only as a Team
This systematic review and meta-analysis evaluated immune checkpoint inhibitor (ICI)-based treatments in EGFR L858R-mutated non-small cell l…
For lung cancer patients with a specific mutation, immune drugs alone fail but work when combined with other treatments to delay progression…
Asciminib superior to IS-TKIs in newly diagnosed CML-CP: MMR 74.1% vs 52.0% at 96 weeks
Could a new leukemia drug work better and cause fewer side effects than current treatments?
In the ASC4FIRST trial, asciminib demonstrated superior efficacy vs investigator-selected TKIs (IS-TKIs) in newly diagnosed CML-CP. At week …
A new leukemia drug helped more patients reach deep disease control with fewer side effects than current standard treatments after two years…